• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparing adverse Events of tenecteplase and alteplase: A Real-World analysis of the FDA adverse Event Reporting System (FAERS)
CONCLUSION: This study identified and compared signals of ADRs associated with tenecteplase and alteplase, although tenecteplase is as effective as alteplase and has advantages such as ease of use and affordability, it cannot replace alteplase in the treatment of AIS until its safety profile is fully recognized. Additionally, previously unreported ocular ADRs and pneumonia were identified, providing valuable insights into the relationship between ADRs and the use of these thrombolytic drugs. These findings underscore the importance of continuous monitoring and effective detection of AEs to ultimately enhance the safety of ...
Source: Expert Opinion on Drug Safety - August 9, 2023 Category: Drugs & Pharmacology Authors: Fang-E Shi Zhe Yu Chengyue Sun Peiliang Gao Haiyan Zhang Jihong Zhu Source Type: research

Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
ConclusionsThis meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results.
Source: Neurology and Therapy - August 8, 2023 Category: Neurology Source Type: research

Effects of predictive nursing intervention on cognitive impairment and neurological function in ischemic stroke patients
ConclusionPredictive nursing intervention is beneficial to improve the effects of thrombolytic therapy in patients with ischemic stroke, which improves the neurological, cognitive and motor functions of patients, and reduces the occurrence of complications, suggesting an important clinical application value.
Source: Brain and Behavior - February 4, 2023 Category: Neurology Authors: Lianyu Xue, Jiangshan Deng, Lingyan Zhu, Feifei Shen, Jiewei Wei, Lihui Wang, Qinqin Chen, Lan Wang Tags: ORIGINAL ARTICLE Source Type: research

E-048 Antithrombotics for emergent stenting in acute stroke
ConclusionTirofiban continuous infusion is a safe and possibly effective strategy for emergent stenting in acute ischemic stroke.Disclosures S. Lahoti: None. K. Limaye: None. C. Zevallos: None. K. Dlouhy: None. M. Hayakawa: None. E. Samaniego: None. D. Hasan: None. S. Ortega: 2; C; Medtronic, Stryker Neurovascular, Microvention. C. Derdeyn: 1; C; Siemens Healthineers. 4; C; Euphrates Vascular, Inc. 6; C; DSMB: Penumbra (MIND), NoNO (ESCAPE NA1 and FRONTIER).
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Lahoti, S., Limaye, K., Zevallos, C., Dlouhy, K., Hayakawa, M., Samaniego, E., Hasan, D., Ortega, S., Derdeyn, C. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

An Optimal Animal Model of Ischemic Stroke Established by Digital Subtraction Angiography-Guided Autologous Thrombi in Cynomolgus Monkeys
ConclusionOur study may provide an optimal non-human primate model for an in-depth study of the pathogenesis and treatment of focal cerebral ischemia.
Source: Frontiers in Neurology - April 25, 2022 Category: Neurology Source Type: research

Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study
Benefit of thrombolytic therapy in patients with acute stroke, who are on anticoagulant treatment, is not well addressed. The aim of this study was to investigate whether apixaban can modify the thrombolytic efficacy of alteplase in vitro. Static and flow models and two variants of red blood cell (RBC) dominant clots, with and without apixaban, were used. Clots were prepared from the blood of healthy human donors and subsequently exposed to alteplase treatment. Apixaban and alteplase were used in clinically relevant concentrations. Clot lysis in the static model was determined both by clot weight and spectrophotometric det...
Source: Frontiers in Pharmacology - September 15, 2021 Category: Drugs & Pharmacology Source Type: research

Fucoidan-functionalized polysaccharide submicroparticles loaded with alteplase for efficient targeted thrombolytic therapy
Biomaterials. 2021 Aug 30;277:121102. doi: 10.1016/j.biomaterials.2021.121102. Online ahead of print.ABSTRACTIntravenous administration of fibrinolytic drugs is the standard treatment of acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short plasma half-lives and might trigger hemorrhagic transformations. Therefore, it is mandatory to develop innovative nanomedicine-based solutions for more efficient and safer thrombolysis with biocompatible and biodegradable thrombus-targeted nanocarrier. Herein, fucoidan-functionalized hydrogel polysaccharide submicroparticles w...
Source: Biomaterials - September 5, 2021 Category: Materials Science Authors: Alina Zenych Charl ène Jacqmarcq Rachida Aid Louise Fournier Laura M Forero Ramirez Fr édéric Chaubet Thomas Bonnard Denis Vivien Didier Letourneur C édric Chauvierre Source Type: research

Tenecteplase for Acute Ischemic Stroke Treatment
Semin Neurol DOI: 10.1055/s-0040-1722722The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis wi...
Source: Seminars in Neurology - January 20, 2021 Category: Neurology Authors: Baird, Alison E. Jackson, Richard Jin, Weijun Tags: Review Article Source Type: research

Efficacy and safety of intravenous thrombolysis with alteplase for treating acute ischemic stroke at different time windows: A protocol for systematic review and meta-analysis
Conclusions: This study will provide an evidence-based basis for the clinical efficacy of alteplase for treating AIS by thrombolytic therapy at different time windows. Ethics and dissemination: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences. OSF Registration number: DOI 10.17605 / OSF.IO / K7PHB
Source: Medicine - December 24, 2020 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research

M2 segment thrombectomy is not associated with increased complication risk compared to M1 segment: A meta-analysis of recent literature
Numerous trials report safety and efficacy of mechanical thrombectomy (MT) for infarcts involving the M1 segment of the middle cerebral artery (MCA; extending from the terminal bifurcation of the internal carotid artery proximally to the main bifurcation distally) in comparison to intravenous thrombolytic therapy (e.g. alteplase) therapy alone.1 –5 The Highly Effective Reperfusion Using Multiple Endovascular Devices (HERMES) meta-analysis of these early studies reported a number needed to treat of 2.6 for MT to reduce the modified Rankin Scale (mRS) by 1 point.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: Christopher Alexander, Andrew Caras, William Kyle Miller, Rizwan Tahir, Tarek R. Mansour, Azedine Medhkour, Horia Marin Source Type: research

Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature
ConclusionFurther integrated processes are required to maximise patient benefit from thrombolysis. Expansion of community education to incorporate less common symptoms and provision of alert pagers for patients may provide further reduction in thrombolysis times.
Source: Journal of Neurology - March 20, 2020 Category: Neurology Source Type: research

Pages: 1  2  3